Journal of Nuclear Medicine February 2025, jnumed.124.268612; DOI: https://doi.org/10.2967/jnumed.124.268612 A key challenge in advancing RPTs is variability in AD ...

Following the Food and Drug Administration’s approval of Lutathera and Pluvicto in 2018 and 2022, respectively, we predicted ...

Cancer therapy has advanced with molecularly targeted approaches and immunotherapy, yet chemotherapy remains essential for ...

Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New ...

The Chinese Society of Nuclear Medicine conducted a national nuclear medicine survey in January 2024. The purpose of the survey was to update the data from 2019 and provide a scientific basis for ...

Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1920; ...

Journal of Nuclear Medicine February 2025, jnumed.124.269024; DOI: https://doi.org/10.2967/jnumed.124.269024 ...

Journal of Nuclear Medicine February 2025, jnumed.124.267855; DOI: https://doi.org/10.2967/jnumed.124.267855 ...

Journal of Nuclear Medicine February 2025, jnumed.124.268835; DOI: https://doi.org/10.2967/jnumed.124.268835 ...

Journal of Nuclear Medicine February 2025, jnumed.124.268079; DOI: https://doi.org/10.2967/jnumed.124.268079 ...

Objectives Acetyl-L-Carnitine (ALC) has been described as playing a neuroprotective effect against a variety of substances. However, the molecular mechanisms underlying its action, particularly ...